3,402 results on '"Thrombocythemia, Essential"'
Search Results
152. 原发性血小板增多症及真性红细胞增多症患者炎性指标与 血栓事件的相关性研究.
153. Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms
154. Recent insights regarding the molecular basis of myeloproliferative neoplasms
155. Familial Myeloproliferative Disorders
156. Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia (FAST)
157. Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders
158. Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
159. Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases
160. Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
161. Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
162. Primary Thrombocythaemia 1 Trial (PT-1)
163. Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
164. A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis
165. Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia (ARETA)
166. HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET
167. Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders
168. Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
169. Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera (ET/PV)
170. Therapiestrategien bei myeloproliferativen Neoplasien
171. Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
172. Anagrelide Retard in Essential Thrombocythemia (TEAM-ET)
173. LBH589 (Panobinostat) for the Treatment of Myelofibrosis
174. Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) (MACS2030)
175. 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
176. The Pitfalls of Global Hemostasis Assays in Myeloproliferative Neoplasms and Future Challenges.
177. CHIP-JAK2V617F, chronic inflammation, abnormal megakaryocyte morphology, organ failure, and multimorbidities.
178. Essential thrombocythaemia first presenting as myocardial infarction in a 36-year-old male
179. Anti-TGF-beta Therapy in Patients With Myelofibrosis
180. CEP-701 (Lestaurtinib) in Myelofibrosis
181. Molecular prognostication in Ph-negative MPNs in 2022
182. Causes of Thrombocytosis: A Single-center Retrospective Study of 1,202 Patients
183. Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly
184. Lenalidomide and Prednisone in Treating Patients With Myelofibrosis
185. Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
186. Imatinib Mesylate in Treating Patients With Myelofibrosis
187. Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms
188. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia
189. Neutrophil–lymphocyte ratio and carotid plaque burden in patients with essential thrombocythemia and polycythemia vera
190. Increased cleavage of von Willebrand factor by ADAMTS13 may contribute strongly to acquired von Willebrand syndrome development in patients with essential thrombocythemia
191. Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia
192. Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
193. Myeloproliferative Neoplasms and Bone Structure
194. Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
195. Hemorrhages in Polycythemia Vera and Essential Thrombocythemia: Epidemiology, Description, and Risk Factors—Learnings from a Large Cohort
196. Study of CALR, MPL, and c-kit Gene Mutations in Thai Patients with JAK2 V617F Negative Myeloproliferative Neoplasms
197. CRLF3 plays a key role in the final stage of platelet genesis and is a potential therapeutic target for thrombocythemia
198. A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
199. A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia
200. A Safety Study of XL019 in Adults With Myelofibrosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.